David Braun

1/ Recently, our lab has worked with outstanding groups (#TeamScience) to address some key questions in kidney cancer immunobiology: Can we use machine-learning approaches to classify RCC and predict response? @Cancer_Cell What drives exceptional response with immunotherapies?…

🎉 Thanks to @CancerResearch for funding two additional #kidneycancer-focused grants in addition to a joint KCA-CRI CLIP award - a total of $900K in new immunotherapy research funding! 🏆 Congratulations to @BraunMDPhD @may_alley @sidichen! kidneycancer.org/cri-clip-award…

"This [was] the first proof of concept of this idea of a personalized cancer vaccine targeting neoantigens in kidney cancer," said David A. Braun, MD, PhD. hubs.li/Q03yF6bJ0 #kcsm | @BraunMDPhD @YaleCancer

Proud to present our work at #KCRS25 on CAR-T screens, cell therapy and kidney cancer from @YaleMed @YaleGenetics @YaleWestCampus @YaleCancer Honored to be in session with Drs. Chuck Drake at JnJ, Nadal Rios at Hutch & Patrick Ott at Farber, hosted by David Braun &Hans Hammers.

How Personalized Cancer Vaccines Are Advancing Kidney Cancer Care @BraunMDPhD @YaleCancer @YaleMed @kidneycan #KidneyCancer #KCRS25 curetoday.com/view/how-perso…

ENPP3 might be the PSMA of kidney cancer. 93% of ccRCC express it on the membrane a perfect door for ADCs. C. Drake @JanssenUS @kidneycan @IKCCorg @DrChoueiri @HHammersMD @OncoAlert @montypal @NazliDizman @yekeduz_emre @AlbigesL @MikeSerzanMD @arihakimi @ReneeSaliby…

Strategies for rare kidney cancer subtypes: addressed by @bilenma at #KCRS25 A reminder: each subtype deserves tailored solutions. @kidneycan @IKCCorg @DrChoueiri @HHammersMD @OncoAlert @montypal @NazliDizman @yekeduz_emre @AlbigesL @MikeSerzanMD @arihakimi @ReneeSaliby…

Thank you @CJSTRAV3 @kidneycan

So proud of my lab representing at #KCRS2025… Amazing meeting with amazing people!

Investigational Neoantigen Vaccines Target RCC Mutations and Drive Durable T-Cell Activity @BraunMDPhD @YaleCancer #KCRS2025 onclive.com/view/investiga…

Congratulations to @BraunMDPhD + @sidichen for being named Clinical Laboratory Integration Program (CLIP) awardees by @CancerResearch! CLIP supports early-phase studies that test the translational potential of new immunotherapy approaches. medicine.yale.edu/news-article/d… @SmilowCancer…

🎉 CRI is proud to announce the 2025 CLIP and Technology Impact Award projects, a new class of high‑potential studies and tools designed to push cancer immunotherapy further and faster! Explore: bit.ly/4lzfuZi #Immunotherapy #CancerResearch #CancerResearcher

Look at some of the impact of DOD CDMRP funding. @BraunMDPhD is presenting the personalized vaccine in RCC published in @Nature. Please restore funding. It went from $50 Million to $0 Dollars. We have not solved cancer yet! @kidneycan #KCRS25

🎙️Live at #KCRS2025, we just spoke with David Braun, MD, PhD, about his presentation on personalized vaccines in kidney cancer. Look out for additional video coverage on our website! #kcsm | @BraunMDPhD | @kidneycan

Brilliant tumor-agnostic trial insights by @VivekSubbiah at #KCRS25: ✅ Every target is pan-target ✅ No “undruggable” targets ✅ Patients can’t wait! We can fine-tune later, but we must start now. @kidneycan @IKCCorg @advocatekidneys @DrChoueiri @HHammersMD @OncoAlert @montypal…

And we're off! #KCRS25 begins with an important session on variant histologies of RCC, with @BradMcG04 giving an overview of papillary RCC @KidneyCancer

📢KCRS25 kicks off! 👏Truly inspired by the focus on non-clear cell renal cell carcinoma at #KCRS25. An area with important progress through clinical and translational efforts, yet still an immense need to collaborate and accelerate discovery for patients who have long been…

#KCRS25 Oral Abstract: @MarcMachaalani @DanaFarber highlights KIM-1 as a potential blood biomarker to predict RCC treatment response and prognosis. Read all the abstracts: bit.ly/AbstractsKCRS25 Register: bit.ly/RegisterKCRS25 #AcceleratingCures

The #KCRS25 meeting by @KidneyCAN brings together basic 🔬, translational 🔗, and clinical trial 🧪 experts in RCC to tackle challenges and drive progress 🚀. The RCC community is passionate ❤️ and dedicated to improving outcomes for patients 🙌🎗️.

Tomorrow in Boston, we will change Kidney Cancer worldwide. KCRS 2025 unites scientists, translational researchers, clinical oncologists, industry leaders, and patient advocates all in one room for a seamless exchange of ideas that ensures research aligns with real patient needs.

The momentum continues at #KCRS25! 🕚 11am: From Federal Funding to Patient Impact Moderated by @EJonasch, featuring insights on clinical trial consortia, vaccines in kidney cancer w @BraunMDPhD, & more 🕐 1pm: @MikeSerzanMD on Genetic Evaluation & Screening for Early Detection